Sinopharm : ANNOUNCEMENT PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE YEAR ENDED 31 DECEMBER 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司 )

(Stock Code: 01099)

ANNOUNCEMENT

PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD

FOR THE YEAR ENDED 31 DECEMBER 2020

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 15 March 2021 (the "Announcement") in relation to the announcement on preliminary financial data for the year ended 31 December 2020 (the "Reporting Period") of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares)(collectively with its subsidiaries, the "Sinopharm Accord Group").

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the year ended 31 December 2020 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD

Unit: Ten thousand Yuan

Currency: RMB

Items	The Reporting	Same period of last year	Increase/Decrease (%)
Period	Before	After	After adjustment
adjustment	adjustment
Total operating revenue	5,964,945.50	5,204,576.41	5,278,680.75	13.00
Operating profit	216,384.11	183,554.75	183,042.96	18.21
Total profit	215,723.64	185,665.81	185,145.62	16.52
Net profit attributable
to shareholders of the	140,189.26	127,128.92	126,793.13	10.57
listed company
Basic earnings per share (yuan)	3.27	2.97	2.96	10.47
Weighted average ROE	10.49%	10.43%	10.31%	increased by 0.18 percentage point
At the beginning of the	Increase/Decrease
At the end of the	Reporting Period	(%)
Reporting Period	Before	After	After adjustment
adjustment	adjustment
Total assets	3,959,453.35	3,352,060.91	3,402,884.32	16.36
Equity attributable to
shareholders of the	1,394,832.27	1,280,641.09	1,291,114.04	8.03
listed company
Share capital ((in 0'000 shares)	42,812.70	42,812.70	42,812.70	0.00
Net assets attributable to shareholders of the listed company per share (yuan)	32.58	29.91	30.16	8.02

Increase/Decrease

increased by 0.18

Increase/Decrease

Note 1: In 2020, Sinopharm Accord Group acquired 75.00% equity interest in Shanghai Pudong New Area Medical Materials Co., Ltd. (上海浦東新區醫藥藥材有限公司, "Shanghai Pudong") which is under the same control as the Sinopharm Accord Group. When preparing the comparison table of the consolidated financial statements of Sinopharm Accord Group for the year 2020, it is deemed that Sinopharm Accord Group has consolidated the financial statements of Shanghai Pudong from the date when the ultimate controller of the parties to the transaction controlled Shanghai Pudong, and the financial data of the same period last year is so adjusted.

Note 2: The financial data as at the end of the Reporting Period are filled in according to the consolidated financial statements of Sinopharm Accord.

Note 3: The net profit attributable to the shareholders of the listed company for the Reporting Period increased by 10.57% as compared to the same period last year, which is mainly due to the increase in the sales scale of pharmaceutical retail business of Sinopharm Accord Group as well as the incremental performance brought by acquired companies. As a result, the basic earnings per share has increased by

10.47% as compared to the same period last year, and the weighted average ROE increased by 0.18 percentage point as compared to the same period last year.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

In 2020, under the influence of , among others, the COVID - 19 pandemic and the policy of volume-based procurement, the industry structure has been reconstructed continuously, and the industry concentration has been further enhanced. Sinopharm Accord has balanced and planned the pandemic prevention and control with its operation and development, and solidly promoted various work, which not only accomplished the major task of fighting against the pandemic and guaranteeing supply, but also withstood the huge impact of the pandemic and its business performance has reached a new height.

For the year of 2020, Sinopharm Accord recorded an operating revenue of RMB59,649 million and an operating profit of RMB2,164 million, representing a year-on-year increase of 13.00% and 18.21%, respectively. The net profit attributable to shareholders of the listed company was RMB1,402 million, representing a year-on year increase of 10.57%.

The distribution business segment recorded an operating revenue of RMB41,070 million and a net profit of RMB855 million, representing a year-on-year increase of 2.64% and 1.06%, respectively. The retail business segment recorded an operating revenue of RMB19,438 million and a net profit of RMB477 million, representing a year-on-year increase of 44.04% and 54.81%, respectively.

By order of the Board Sinopharm Group Co. Ltd.

Yu Qingming

Chairman

Shanghai, the PRC

15 March 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies

Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."